These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 10803497)

  • 1. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
    Yu T; Bai Y; Dierich MP; Chen YH
    Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
    Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
    Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
    Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
    Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
    Tian H; Xiao Y; Qin L; Chen YH
    Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1.
    Ding J; Lu Y; Chen Y
    FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and specificity of the candidate multi-epitope-vaccines against HIV-1.
    Lu Y; Ding J; Chen YH
    Immunopharmacol Immunotoxicol; 2001 Nov; 23(4):487-94. PubMed ID: 11792008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies.
    Tian H; Xiao Y; Zhu M; Chen YH
    Int Immunopharmacol; 2001 Apr; 1(4):763-8. PubMed ID: 11357888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
    Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
    Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F; Keller H; Kieny MP; Thèze J
    Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
    Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
    Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
    Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
    J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features.
    Gazarian KG; Palacios-Rodríguez Y; Gazarian TG; Huerta L
    Mol Immunol; 2013 Jun; 54(2):148-56. PubMed ID: 23270686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ
    AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody.
    Xiao Y; Zhao Y; Lu Y; Chen YH
    Immunol Invest; 2000 Feb; 29(1):41-50. PubMed ID: 10709845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.